HK143295A - Fsh - Google Patents

Fsh Download PDF

Info

Publication number
HK143295A
HK143295A HK143295A HK143295A HK143295A HK 143295 A HK143295 A HK 143295A HK 143295 A HK143295 A HK 143295A HK 143295 A HK143295 A HK 143295A HK 143295 A HK143295 A HK 143295A
Authority
HK
Hong Kong
Prior art keywords
fsh
beta subunit
cell
vector
subunit
Prior art date
Application number
HK143295A
Other languages
English (en)
French (fr)
Inventor
Yemuri S. Reddy
Hsiung Nancy
Anton K. Beck
George Bernstine Edward
Original Assignee
Applied Research Systems Ars Holding N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24797972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK143295(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems Ars Holding N.V. filed Critical Applied Research Systems Ars Holding N.V.
Publication of HK143295A publication Critical patent/HK143295A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/60—Vector systems having a special element relevant for transcription from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (23)

  1. Verfahren zur Herstellung von biologisch aktivem, heterodimeren, menschlichen follikelstimulierenden Hormon (FSH), welches eine Alpha-Untereinheit und eine Beta-Untereinheit besitzt, wobei die reife Beta-Untereinheit die folgende Sequenz aufweist: und das Verfahren die gemeinsame Synthese jeder der Untereinheiten in einer eukaryotischen Zelle umfaßt, die mit einem oder mehr Expressionsvektoren transfektiert ist, der heterologe DNA zur Codierung jeder der Untereinheiten beinhaltet.
  2. Verfahren zur Herstellung der Beta-Untereinheit von menschlichem FSH, welches das Kultivieren von Wirtszellen umfaßt, die mit einem Expressionsvektor transfektiert sind, der heterologe DNA beinhaltet, welche die Beta-Untereinheit von FSH codiert, wobei die reife Beta-Untereinheit die folgende Sequenz aufweist:
  3. Verfahren zur Herstellung der unreifen Beta-Untereinheit von menschlichem FSH, welches das Kultivieren von Wirtszellen umfaßt, die mit einem Expressionsvektor transfektiert sind, der heterologe DNA beinhaltet, welche die unreife Beta-Untereinheit von FSH codiert, wobei die unreife Beta-Untereinheit die in Anspruch 2 angeführte Sequenz der reifen Beta-Untereinheit besitzt und zusätzlich die folgende Leader-Sequenz aufweist:
  4. Verfahren nach Anspruch 1, wobei die Beta-Untereinheit des FSH durch heterologe DNA eines ersten Expressionsvektors codiert wird und die Alpha-Untereinheit des FSH durch heterologe DNA eines zweiten Expressionsvektors codiert wird, der in die Wirtszelle transfektiert ist.
  5. Verfahren nach Anspruch 1, wobei beide Untereinheiten des FSH von heterologer DNA eines einzigen Expressionsvektors codiert werden.
  6. Verfahren zur Herstellung von DNA, welche die Beta-Untereinheit von menschlichem FSH codiert, wobei die reife Beta-Untereinheit die folgende Sequenz aufweist: und das Verfahren DNA-Ligation und/oder Synthese umfaßt.
  7. Verfahren nach Anspruch 6, wobei die rekombinante DNA die Form eines Vektors aufweist.
  8. Verfahren nach Anspruch 7, wobei der Vektor ein Expressionsvektor ist, der eine eukaryotische Zelle transformieren kann.
  9. Verfahren nach Anspruch 7, wobei der Vektor die NRRL-Zugriffsnummer B-15923 besitzt.
  10. Verfahren nach Anspruch 7, wobei die rekombinante zusätzlich die folgende Leader-Sequenz der Beta-Untereinheit codiert:
  11. Verfahren zur Herstellung von zwei Expressionsvektoren, das die Herstellung eines ersten Expressionsvektors, der heterologe DNA, welche die Beta-Untereinheit von menschlichem FSH codiert, beinhaltet, durch DNA-Ligation und/oder Synthese umfaßt, wobei die reife Beta-Untereinheit die folgende Sequenz aufweist: sowie die Herstellung eines zweiten Expressionsvektors, der heterologe DNA, welche die Alpha-Untereinheit von menschlichem FSH codiert, beinhaltet, durch DNA-Ligation und/oder Synthese.
  12. Verfahren zur Herstellung eines Expressionsvektors, wobei der Vektor heterologe DNA umfaßt, welche die Alpha- und Beta-Untereinheiten des biologisch aktiven, heterodimeren FSH codiert, und das Verfahren DNA-Ligation und/oder Synthese umfaßt und wobei die reife Beta-Untereinheit die folgende Sequenz aufweist:
  13. Verfahren zur Herstellung einer transfektierten eukaryotischen Zelle, welches die Transfektion der Zelle mit einem oder mehr Expressionsvektoren umfaßt, wobei die transfektierte Zelle imstande ist, das biologisch aktive heterodimere FSH zu erzeugen, wobei die Alpha- und Beta-Untereinheiten von FSH von heterologer DNA in dem oder den Expressionsvektor(en) codiert werden und wobei die reife Beta-Untereinheit die folgende Sequenz aufweist:
  14. Verfahren nach Anspruch 13, wobei der Expressionsvektor zusätzlich für die folgende Leader-Sequenz der Beta-Untereinheit codiert:
  15. Verfahren nach Anspruch 13 oder 14, wobei die Zelle eine Säugetierzelle ist.
  16. Verfahren nach Anspruch 13, 14 oder 15, wobei der Vektor oder jeder der Vektoren zumindest 69% des Transformationsbereichs des Rinderpapillomavirusgenoms enthält.
  17. Verfahren nach jedem der Ansprüche 13 bis 16, wobei die Zelle eine Mauszelle ist.
  18. Verfahren nach jedem der Ansprüche 13 bis 17, wobei der oder jeder Vektor ein Plasmid umfaßt.
  19. Verfahren nach Anspruch 1, welches die Gewinnung von FSH aus einer Kultur der Zellen umfaßt.
  20. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, welches die Herstellung von rekombinantem FSH durch ein Verfahren nach Anspruch 1 und das Zusetzen des so hergestellten FSH zu einem Träger umfaßt.
HK143295A 1985-01-30 1995-09-07 Fsh HK143295A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/696,647 US4923805A (en) 1983-11-02 1985-01-30 Fsh

Publications (1)

Publication Number Publication Date
HK143295A true HK143295A (en) 1995-09-15

Family

ID=24797972

Family Applications (1)

Application Number Title Priority Date Filing Date
HK143295A HK143295A (en) 1985-01-30 1995-09-07 Fsh

Country Status (12)

Country Link
US (1) US4923805A (de)
EP (2) EP0521586B1 (de)
JP (5) JPH0724584B2 (de)
KR (1) KR910002692B1 (de)
AT (1) ATE87317T1 (de)
DE (3) DE211894T1 (de)
DK (2) DK171601B1 (de)
HK (1) HK143295A (de)
LU (1) LU88738I2 (de)
MX (1) MX9203681A (de)
NL (1) NL960004I2 (de)
WO (1) WO1986004589A1 (de)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455282B1 (en) 1983-11-02 2002-09-24 Genzyme Corporation Cells, vectors and methods for producing biologically active TSH
US5156957A (en) * 1983-11-02 1992-10-20 Genzyme Corporation Follicle stimulating hormone
US5639639A (en) * 1983-11-02 1997-06-17 Genzyme Corporation Recombinant heterodimeric human fertility hormones, and methods, cells, vectors and DNA for the production thereof
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
US4921808A (en) * 1986-06-25 1990-05-01 The Albany Medical College Of Union University Method for determining follicle stimulating hormone
US6150328A (en) * 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
IT1206302B (it) * 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
EP0453482A4 (en) 1989-01-11 1992-07-22 Us Health Biologically active synthetic thyrotropin and cloned gene for producing same
US6225449B1 (en) * 1991-10-04 2001-05-01 Washington University Hormone analogs with multiple CTP extensions
ATE148171T1 (de) * 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
US5338835A (en) * 1989-02-21 1994-08-16 Washington University CTP-extended form of FSH
US5087615A (en) * 1989-03-17 1992-02-11 Applied Research Systems Ars Holding N.V. Novel method of ovulation induction in humans
EP0404458A3 (de) * 1989-06-19 1992-03-04 Bunge (Australia) Proprietary Limited Follikelstimulierendes Schafhormon
US5240832A (en) * 1989-06-20 1993-08-31 Genzyme Corporation Heteropolymeric protein production methods
US20080139474A1 (en) * 1991-11-04 2008-06-12 David Israel Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
DE69233022T2 (de) * 1991-11-04 2004-02-12 Genetics Institute, LLC, Cambridge Rekombinante knochenmorphogenetische protein heterodimere, zusammensetzungen und verfahren zur verwendung
US6291206B1 (en) * 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US6238890B1 (en) * 1994-02-18 2001-05-29 Washington University Single chain forms of the glycoprotein hormone quartet
US6727224B1 (en) * 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
JP2002541213A (ja) 1999-04-13 2002-12-03 インヘール セラピューティック システムズ， インコーポレイテッド 不妊症の処置のための乾燥粉末処方物の肺投与
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
US6824822B2 (en) * 2001-08-31 2004-11-30 Alkermes Controlled Therapeutics Inc. Ii Residual solvent extraction method and microparticles produced thereby
US20030082233A1 (en) * 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
WO2002099037A2 (en) * 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) * 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
EP2042196B1 (de) 2001-10-10 2016-07-13 ratiopharm GmbH Neumodellierung und Glykokonjugation von Granulozyten-Kolonie stimulierender Faktor (G-CSF)
NZ535008A (en) * 2002-02-08 2005-09-30 Alkermes Inc Polymer-based compositions for sustained release
TW200638946A (en) * 2002-05-17 2006-11-16 Wyeth Corp Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins
NZ542549A (en) * 2003-03-04 2008-11-28 Aspenbio Pharma Inc Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using single-chain luteinizing hormone
NZ542586A (en) 2003-04-09 2009-11-27 Biogenerix Ag Method of forming a covalent conjugate between a G-CSF peptide and PEG
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
UA88879C2 (en) * 2003-09-02 2009-12-10 Эплайд Рисерч Системз Эрс Холдинг Н.В. Fsh glycosylation mutant
DE602004005477T2 (de) * 2003-09-12 2007-12-13 Wyeth Injizierbare feste Calciumphosphat-Stäbe zur Abgabe von osteogenen Proteinen
KR100533794B1 (ko) * 2003-10-02 2005-12-07 주식회사 프로젠 인간 난포자극 호르몬을 대량으로 생산하는 방법
KR100587535B1 (ko) * 2004-02-04 2006-06-08 충남대학교산학협력단 재조합 ｈＦＳＨ 유전자 및 이를 내장하는 발현용 벡터
US20060110423A1 (en) * 2004-04-15 2006-05-25 Wright Steven G Polymer-based sustained release device
US7456254B2 (en) * 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
PL2409707T3 (pl) 2004-04-15 2015-08-31 Amylin Pharmaceuticals Llc Urządzenie o przedłużonym uwalnianiu na bazie polimeru
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
US20100069387A1 (en) 2005-09-07 2010-03-18 Palmer Stephen S IKK Inhibitors for the Treatment of Endometriosis
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
UA103598C2 (uk) 2007-06-28 2013-11-11 Биодженерикс Аг Клон клітин, що продукують fsh
EP2412385A1 (de) 2008-02-08 2012-02-01 BioGeneriX AG Flüssige Formulierung von FSH
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
JP2009273427A (ja) 2008-05-16 2009-11-26 Jcr Pharmaceuticals Co Ltd 組換え体ヒトｆｓｈの製造方法
KR101761168B1 (ko) 2009-04-01 2017-07-25 바이오제너릭스 게엠베하 재조합 ｆｓｈ 정제 방법
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
EP2325194A1 (de) 2009-11-24 2011-05-25 Glycotope GmbH Verfahren zur Reinigung von Glykoproteinen
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN103509121B (zh) 2012-11-22 2015-01-28 苏州康宁杰瑞生物科技有限公司 一种fsh融合蛋白及其制备方法和用途
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468464A (en) * 1974-11-04 1984-08-28 The Board Of Trustees Of The Leland Stanford Junior University Biologically functional molecular chimeras
JPS586475B2 (ja) 1980-08-23 1983-02-04 株式会社 林原生物化学研究所 ヒト絨毛性性腺刺激ホルモンの製造方法
JPS585671B2 (ja) * 1980-08-27 1983-02-01 株式会社 林原生物化学研究所 ヒト卵胞刺激ホルモンの製造方法
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4840896A (en) * 1983-11-02 1989-06-20 Integrated Genetics, Inc. Heteropolymeric protein
ATE169334T1 (de) * 1983-11-02 1998-08-15 Applied Research Systems Herstellung heterodimirer menschlicher fruchtbarkeitshormone
DE3520404C2 (de) * 1984-06-08 1994-06-16 Genzyme Corp Schweine-ß-FSH
WO1986000923A1 (en) * 1984-07-31 1986-02-13 Integrated Genetics, Inc. Yeast cloning vehicles

Also Published As

Publication number Publication date
JPH09173064A (ja) 1997-07-08
JPS63500212A (ja) 1988-01-28
DE3688109T2 (de) 1993-07-15
JPH07255492A (ja) 1995-10-09
JPH06253884A (ja) 1994-09-13
DE211894T1 (de) 1991-06-13
JPH0829106B2 (ja) 1996-03-27
WO1986004589A1 (en) 1986-08-14
DE19675006I2 (de) 2008-06-12
EP0211894A1 (de) 1987-03-04
ATE87317T1 (de) 1993-04-15
LU88738I2 (fr) 1996-08-23
JPH0724584B2 (ja) 1995-03-22
EP0211894A4 (de) 1987-10-12
EP0211894B1 (de) 1993-03-24
DK171601B1 (da) 1997-02-17
JP2683563B2 (ja) 1997-12-03
EP0521586A1 (de) 1993-01-07
NL960004I1 (nl) 1996-09-02
DK463586A (da) 1986-09-29
DK172625B1 (da) 1999-03-15
KR910002692B1 (ko) 1991-05-03
EP0521586B1 (de) 1999-06-23
KR870700074A (ko) 1987-02-28
JP2757982B2 (ja) 1998-05-25
DE3688109D1 (en) 1993-04-29
DK463586D0 (da) 1986-09-29
NL960004I2 (nl) 1997-04-01
JP2559196B2 (ja) 1996-12-04
DK144695A (da) 1995-12-20
US4923805A (en) 1990-05-08
MX9203681A (es) 1992-09-01
JPH07241194A (ja) 1995-09-19

Similar Documents

Publication Publication Date Title
EP0211894B1 (de) Fsh
US5767251A (en) Recombinant heterodimeric human fertility hormones, and methods, cells, and vectors and DNA for the production thereof
US5856137A (en) Nucleic acids encoding and recombinant production of the β subunit of lutenizing hormone
EP0285448B1 (de) Leukämie hemmender Faktor
EP0578328B1 (de) Produkte und Methoden für die Herstellung einer heterodimerer menschlicher LH mit einem Met42 Val55 alpha Untereinheit
JP2541761B2 (ja) ミュレル管抑制物質様ポリペプチドおよびその製造方法
JPH0217156B2 (de)
JPH0435159B2 (de)
JPS63500843A (ja) 組換え繊維芽細胞成長因子
US5156957A (en) Follicle stimulating hormone
D'Amore et al. Complete sequence and organization of the murine. beta.-glucuronidase gene
US5840566A (en) Isolation of a gene encoding human thyrotropin beta subunit
US4717670A (en) Porcine beta FSH
IE904639A1 (en) Bovine myogenic factor gene
HU204086B (en) Process for producing non-human mammal animal interferons, dna sequemces coding form them and pharmaceutical compositions comprising sand interferons
CA2032842A1 (en) Bovine myogenic factor gene

Legal Events

Date Code Title Description
CHPA Change of a particular in the register (except of change of ownership)
PF Patent in force
PE Patent expired

Effective date: 20060129